Frequency of HER-2 Positivity in Rectal Cancer and Prognosis
暂无分享,去创建一个
T. Beißbarth | J. Rüschoff | C. Rödel | L. Conradi | J. Gaedcke | H. Styczen | H. Becker | T. Liersch | T. Sprenger | K. Homayounfar | H. Wolff | P. Middel | M. Ghadimi | M. Nietert | J. Kitz | R. Talaulicar | T. Beissbarth
[1] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[2] Torsten Hothorn,et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. , 2012, The Lancet. Oncology.
[3] M. Vijver,et al. HER2 testing in gastric cancer: a practical approach , 2012, Modern Pathology.
[4] Jeffrey W. Clark,et al. Cancers of the colon and rectum: identical or fraternal twins? , 2012, Cancer discovery.
[5] Tsung-Teh Wu,et al. Association of HER2/ErbB2 Expression and Gene Amplification with Pathologic Features and Prognosis in Esophageal Adenocarcinomas , 2012, Clinical Cancer Research.
[6] W. Hohenberger,et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] A. Ullrich,et al. Toward the Prognostic Significance and Therapeutic Potential of HER3 Receptor Tyrosine Kinase in Human Colon Cancer , 2011, Clinical Cancer Research.
[8] Davide Corà,et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. , 2011, Cancer discovery.
[9] T. Fukuda,et al. Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric cancer based on the randomised ToGA trial , 2011, British Journal of Cancer.
[10] M. Ychou,et al. EGFR and HER3 mRNA expression levels predict distant metastases in locally advanced rectal cancer , 2011, International journal of cancer.
[11] M. Odenthal,et al. β-catenin and Her2/neu expression in rectal cancer: association with histomorphological response to neoadjuvant therapy and prognosis , 2011, International Journal of Colorectal Disease.
[12] T. Beißbarth,et al. Gender-specific acute organ toxicity during intensified preoperative radiochemotherapy for rectal cancer. , 2011, The oncologist.
[13] J. Nortier,et al. Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer. , 2010, Cancer treatment reviews.
[14] C. Hess,et al. [Rectal cancer: current status of multimodal therapy--when and how?]. , 2011, Zentralblatt fur Chirurgie.
[15] O. Bouché,et al. HER2 et cancer de l'estomac : une nouvelle cible thérapeutique pour le trastuzumab , 2010 .
[16] F. Penault-Llorca,et al. [HER2 and gastric cancer: a novel therapeutic target for trastuzumab]. , 2010, Bulletin du cancer.
[17] C. Compton,et al. TNM seventh edition: What's new, what's changed , 2010, Cancer.
[18] K. Bujko,et al. Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] Yoon-Koo Kang,et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.
[20] Manfred Dietel,et al. HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing , 2010, Virchows Archiv.
[21] Thomas Seufferlein,et al. Targeted treatments in colorectal cancer: state of the art and future perspectives , 2010, Gut.
[22] H. Höfler,et al. [Her2 testing in gastric cancer. What is different in comparison to breast cancer?]. , 2010, Der Pathologe.
[23] H. Christiansen,et al. Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: Do we have indications for individual risk stratification? , 2010, World journal of surgical oncology.
[24] C. Rödel. Preoperative chemoradiotherapy for rectal cancer , 2010 .
[25] Peter Dalgaard,et al. R Development Core Team (2010): R: A language and environment for statistical computing , 2010 .
[26] T. Beißbarth,et al. Preoperative Chemoradiotherapy Does Not Necessarily Reduce Lymph Node Retrieval in Rectal Cancer Specimens—Results from a Prospective Evaluation with Extensive Pathological Work-up , 2009, Journal of Gastrointestinal Surgery.
[27] M. J. van de Vijver,et al. Emerging technologies for assessing HER2 amplification. , 2009, American journal of clinical pathology.
[28] I. Nagtegaal,et al. A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned? , 2009, European journal of cancer.
[29] Mitch Dowsett,et al. Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] H. Christiansen,et al. Gold markers for tumor localization and target volume delineation in radiotherapy for rectal cancer , 2009, Strahlentherapie und Onkologie.
[31] T. Seufferlein,et al. S3-Leitlinie „Kolorektales Karzinom” – Aktualisierung 2008 , 2008, Zeitschrift fur Gastroenterologie.
[32] V. Heinemann,et al. [Update S3-guideline "colorectal cancer" 2008]. , 2008, Zeitschrift fur Gastroenterologie.
[33] C. Rödel,et al. Integration of Novel Agents into Combined-Modality Treatment for Rectal Cancer Patients , 2007, Strahlentherapie und Onkologie.
[34] E. Chmielik,et al. Association between pathologic response in metastatic lymph nodes after preoperative chemoradiotherapy and risk of distant metastases in rectal cancer: An analysis of outcomes in a randomized trial. , 2007, International journal of radiation oncology, biology, physics.
[35] F. Lordick,et al. Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] Bernard Leduc,et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] Laurence Collette,et al. Chemotherapy with preoperative radiotherapy in rectal cancer. , 2006, The New England journal of medicine.
[38] M. O’connell,et al. Surgical Adjuvant Therapy for Colorectal Cancer: Current Approaches and Future Directions , 2006, Annals of Surgical Oncology.
[39] L. Sobin,et al. The “y” symbol: An important classification tool for neoadjuvant cancer treatment , 2006, Cancer.
[40] Rainer Fietkau,et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] A. Harris,et al. REporting recommendations for tumour MARKer prognostic studies (REMARK) , 2005, British Journal of Cancer.
[42] Rainer Fietkau,et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. , 2004, The New England journal of medicine.
[43] I. Nagtegaal,et al. Macroscopic evaluation of rectal cancer resection specimen: clinical significance of the pathologist in quality control. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[45] F. Guillemin,et al. Prognostic implications of downstaging following preoperative radiation therapy for operable T3-T4 rectal cancer. , 1998, International journal of radiation oncology, biology, physics.
[46] J. Chavaudra,et al. Dernières recommandations de l'ICRU pour la prescription, l'enregistrement et le compte rendu de la radiothérapie externe , 1998 .
[47] J. Chavaudra. [Last ICRU recommendations for the prescription, recording and reporting of external bean therapy]. , 1998, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.
[48] S. Andreola,et al. Pathological features of rectal cancer after preoperative radiochemotherapy , 1998, International Journal of Colorectal Disease.
[49] J. Hoffman. Preoperative chemoradiotherapy for rectal cancer. , 1996, Annals of surgery.
[50] R. Aitken,et al. Mesorectal excision for rectal cancer , 1996, The British journal of surgery.
[51] N. Quenville,et al. Correlation of epidermal growth factor receptor and c-erbB2 oncogene product to known prognostic indicators of colorectal cancer. , 1992, Surgical oncology.
[52] A. Ullrich,et al. Expression of the p185 encoded by her2 oncogene in normal and transformed human tissues , 1990, International journal of cancer.
[53] E. McFadden,et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.
[54] R. Heald,et al. The mesorectum in rectal cancer surgery—the clue to pelvic recurrence? , 1982, The British journal of surgery.
[55] A. Satterfield,et al. TREATMENT , 1924, California and western medicine.